ALPCO Diagnostics

What ALPCO Diagnostics does

ALPCO Diagnostics, legally American Laboratory Products Company, Ltd., is a Salem, New Hampshire-based specialty diagnostics company founded in 1991 and privately held under Ampersand Capital Partners ownership. The company develops and distributes immunodiagnostic and molecular diagnostic products for clinical laboratories and life science researchers, organized around three core instrument platforms: the KleeYa flash chemiluminescence random-access analyzer (processing up to 120 samples per hour with results in 30 minutes), the GeneProof-branded myCROBE sample-to-answer PCR system and croBEE 2.0 nucleic acid extraction platform, and the MADx ALEX2 multiplex allergy testing platform (exclusive North American distribution rights). These platforms support a catalog of 724+ products spanning gastroenterology (calprotectin, pancreatic elastase, lactoferrin, H. pylori), infectious disease (STI PCR panels, HIV, CMV, syphilis), specialty allergy (IgE/IgG testing), immunology, endocrinology (insulin, GLP-1), and therapeutic drug monitoring (adalimumab), with both FDA-cleared clinical diagnostics and Research Use Only products. The 2022 merger with Czech Republic-based GeneProof added real-time PCR capabilities and an extensive European distributor network.

ALPCO's business model is primarily transactional kit and reagent sales with per-unit pricing ranging from ~$454 for standard ELISA kits to over $2,000 for advanced automated assays, supplemented by proprietary instrument placements that drive recurring reagent pull-through. Revenue also flows from a catalog of over 600 life science research kits sold to academic and pharmaceutical researchers. The company reaches customers through a North American direct sales force, an e-commerce storefront at alpco.com, and a global distributor network spanning Europe, Asia-Pacific, Latin America, Middle East, Africa, and Oceania. A 2024 strategic partnership with Revvity's EUROIMMUN extends GeneProof's CE-IVD molecular assay distribution across the European Union.

Quality and regulatory posture is a material part of the operating model: ALPCO holds ISO 13485:2016 certification, FDA establishment registration under 21 CFR 820, and MDSAP certification. Marketing is content-driven (scientific webinars, trade shows at MEDICA, AACC/ADLM, and AAAAI, SEO-optimized content hub, email campaigns). The company is led by CEO Erik Allen with a global management team including six VP-level roles covering business development, product management, sales, quality/regulatory, scientific operations, and finance.

Name

ALPCO Diagnostics

Legal name

American Laboratory Products Company, Ltd.

Website

https://www.alpco.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

ALPCO Diagnostics is a Salem, NH-based specialty diagnostics company that develops and distributes proprietary automated immunoassay and PCR instrument platforms and 724+ assay kits across gastroenterology, allergy, infectious disease, endocrinology, and immunology for clinical laboratories and life science researchers globally.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Autoimmune & Allergy Diagnostics (HLAAALAK)

Keywords

• Immunodiagnostic reagents
• Molecular diagnostic kits
• Clinical immunoassays
• ELISA assay kits
• Diagnostic instruments

Headquarters

HQ city

Salem

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Instruments: ALPCO sells proprietary automated diagnostic instruments including the KleeYa chemiluminescence platform, myCROBE PCR system, and croBEE nucleic acid extraction system. These instruments enable walk-away sample-to-answer testing for clinical and life science laboratories.
2. Assay Kits and Reagents: ALPCO generates revenue from the sale of proprietary assay kits including ELISA, chemiluminescence, and PCR kits across specialties such as gastroenterology, infectious disease, allergy, immunology, endocrinology, and diabetes. Products include Calprotectin, Pancreatic Elastase, Insulin, GLP-1, HIV-1, and STI panels.
3. Life Science Research Products: Over 600 kits and reagents for life science research across multiple species and sample types, sold to academic and pharmaceutical researchers. The portfolio covers endocrinology, immunology, gastroenterology, diabetes, and infectious disease research applications.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

ALPCO Diagnostics develops, manufactures, and distributes proprietary immunodiagnostic and molecular diagnostic instruments (KleeYa, myCROBE, croBEE 2.0, ALEX2) together with more than 600 assay kits and reagents for clinical diagnostic laboratories, hospital systems, reference labs, academic researchers, and pharmaceutical/biotech customers. Its specialty focus covers gastroenterology, endocrinology, infectious disease, allergy, immunology, and reproductive health biomarkers, supplied through direct sales in North America and a global distributor footprint of more than 60 countries.

Product overview

ALPCO Diagnostics is a global leader in immunodiagnostics and molecular diagnostics, offering a portfolio of proprietary automated sample-to-answer platforms and diagnostic assays. The core product architecture consists of three main instrument platforms: the KleeYa Flash Chemiluminescence analyzer for automated biomarker testing, the GeneProof molecular diagnostics system (myCROBE sample-to-answer PCR and croBEE nucleic acid extraction), and the MADx ALEX2 multiplex allergy platform for IgE-based testing. These platforms support a comprehensive menu of over 600 diagnostic assays across key specialty areas including gastroenterology (calprotectin, pancreatic elastase, lactoferrin), infectious disease (STI PCR panels, HIV, CMV), allergy (multiplex IgE), immunology (complement system), and endocrinology (insulin, GLP-1). The company also offers plate-based ELISA solutions and the STELLUX chemiluminescence assay product line. Following the 2022 merger with GeneProof, ALPCO expanded from primarily immunoassay-based products to include real-time PCR capabilities, creating an integrated portfolio spanning immunodiagnostics and molecular diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• KleeYa: Flash Chemiluminescence immunoassay platform for automated biomarker testing
• GeneProof
• MADx
• STELLUX
• ALEX2

Products and services

• KleeYa Automated Flash Chemiluminescence Analyzer Proprietary automated chemiluminescence immunoassay instrument that runs ALPCO's specialty biomarker menu (gastrointestinal, endocrine, allergy, infectious disease, and immunology assays) for clinical and research laboratories.
• myCROBE PCR System Automated PCR amplification system used by molecular diagnostic laboratories to detect infectious disease and genetic targets with ALPCO's PCR reagents and kits.
• croBEE 2.0 Nucleic Acid Extraction System Compact benchtop instrument that automates DNA and RNA extraction to streamline sample preparation ahead of PCR amplification in molecular diagnostic laboratories.
• ALEX2 (MADx) Multiplex Allergy Test Multiplex in vitro allergy diagnostic that simultaneously measures total and specific IgE against a comprehensive panel of allergen extracts and components from a single sample.
• STELLUX Chemiluminescence Assays Specialty chemiluminescence immunoassay reagent kits run on the KleeYa platform for quantitative measurement of gastrointestinal, endocrine, and inflammatory biomarkers.
• Calprotectin Immunoturbidimetric Assay Quantitative fecal calprotectin immunoassay for differentiating inflammatory bowel disease from functional gastrointestinal disorders, used by clinical laboratories on routine chemistry analyzers.
• Plate-based ELISA Kits Comprehensive library of enzyme-linked immunosorbent assay kits covering specialty biomarkers across gastroenterology, endocrinology, infectious disease, allergy, and immunology for research and clinical labs.
• GeneProof PCR Kits Molecular diagnostic PCR kits for infectious disease and genetic testing that laboratories run on the myCROBE system or compatible PCR thermocyclers.
• AutoPlex GI Biomarker Panels Curated multi-analyte gastrointestinal biomarker panels run on ALPCO's automated platforms for specialty gastroenterology testing in clinical and research settings.

Quantifiable outcome

• KleeYa platform processes up to 120 samples per hour with single sample results in 30 minutes
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered major and core.

• Revvity's EUROIMMUNmajorChannel Partner/ Reseller/ Distributor · 25 April 2024Revvity's EUROIMMUN and ALPCO-GeneProof announced a strategic partnership in April 2024 to expand the availability of GeneProof PCR kits throughout the European Union. The collaboration combines EUROIMMUN's extensive distribution network and support infrastructure with ALPCO-GeneProof's innovative molecular diagnostic technologies. This partnership enhances GeneProof's CE-IVD molecular assay offerings across the EU market.
• GeneProofcoreStrategic or Co-development Partner · 1 April 2022In April 2022, ALPCO merged with GeneProof, a molecular diagnostics company based in Brno, Czech Republic, creating a global leader in diagnostic products. The merger expands ALPCO's capabilities in immunoassay testing, real-time PCR testing, and laboratory instrumentation. GeneProof's extensive European distribution network combined with ALPCO's North American presence created significant geographic synergies. GeneProof is now part of the NuvinkaDx portfolio of companies.
• NuvinkaDxcoreOthersNuvinkaDx is the parent company of both ALPCO and GeneProof following the 2022 merger. As of July 2025, NuvinkaDx announced significant product and regulatory milestones for its portfolio companies including ALPCO and GeneProof.
• Macro Array Diagnostics (MADx)majorChannel Partner/ Reseller/ DistributorALPCO is the exclusive North American distributor for Macro Array Diagnostics (MADx), distributing the ALEX2 multiplex allergy testing platform and associated IgE and IgG testing products in North America. The MADx ALEX2 platform enables screening of up to 300 allergens including 117 extracts and 183 molecular allergens. ALPCO actively participates in AAAAI Annual Meetings as the MADx North American distributor.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bio-Rad Laboratories: Bio-Rad is a direct peer in specialty IVD and life science research, offering ELISA kits, immunoassay instruments, molecular diagnostics, and a similarly broad catalog serving clinical and research laboratories globally.
• QIAGEN: QIAGEN is a direct peer in molecular diagnostics sample-to-answer workflows and PCR kits for infectious disease, overlapping GeneProof's PCR menu and instrumentation.
• Tecan: Tecan provides automated immunoassay and sample-preparation platforms used by clinical and research laboratories, overlapping ALPCO's KleeYa and croBEE instrument franchises in laboratory workflow automation.
• DiaSorin: DiaSorin specializes in specialty immunodiagnostics and molecular diagnostics with chemiluminescence platforms (LIAISON) and specialty menus (infectious disease, endocrinology, GI), overlapping ALPCO's KleeYa-based specialty assay portfolio.
• Hologic: Hologic is a direct peer in molecular diagnostics, particularly for STI panels and women's health infectious disease, overlapping GeneProof's CT/NG/MG multiplex PCR kit and broader infectious disease menu.
• DRG International: DRG International is a specialty immunoassay vendor focused on endocrinology and specialty biomarkers, overlapping ALPCO's STELLUX/KleeYa endocrinology and immunology assay menu for clinical and research labs.
• QuidelOrtho: QuidelOrtho competes directly in specialty immunoassays and molecular diagnostics for infectious disease and reproductive health, overlapping ALPCO's STI PCR panels and infectious disease menu.

Broad incumbents

• Merck KGaA / MilliporeSigma: MilliporeSigma serves the same life science research customer base as ALPCO with ELISA kits, antibodies, and laboratory reagents across endocrinology, immunology, and cell biology applications.
• Binding Site (Thermo Fisher Scientific): The Binding Site, part of Thermo Fisher, provides specialty immunodiagnostics (e.g., immune globulin, complement, specialty proteins) that directly compete with ALPCO's immunology and complement assays.
• Revvity (PerkinElmer): Revvity's EUROIMMUN division is both a distribution partner and a broad specialty IVD incumbent with autoimmune, infectious disease and allergy diagnostics menus that compete with several of ALPCO's specialty franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/alpco
• Facebookfacebook.com/alpcodiagnostics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALPCO Diagnostics